ResMed shareholders also sleep well at night

August 6, 2018

Sleep device maker ResMed this morning reported a 13% increase in revenue for the year ended 30 June 2018 together with a 27% increase in operating income. Chief Executive, Mick Farrell, was reported as saying that “we closed out the year with strong performance across all aspects of our business, from solid top-line revenue growth, driven by geographically balanced results across our entire portfolio of offerings”.  The company is well positioned for fiscal year 2019.

Resmed is one of Morgan Wealth’s core shareholdings and has produced a return of 47% for the 12 months ended 31 July 2018.

Our Top Recommendations
Total returns on capital growth and dividends for 12 months ended 31 October 2018
Afterpay Touch
141.59%
Altium Limited
80.73%
Relance Worldwide
36.25%
CSL Limited
35.65%
Resmed Inc
34.40%
Lovisa Holdings
31.89%
Xero Ltd
30.09%
Macquarie Group
24.50%
Bingo Industries
23.96%
Atlas Arteria
17.25%
ASX200 Accum Index (comparison)
2.44%